BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sheyi R, de la Torre BG, Albericio F. Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate. Pharmaceutics 2022;14:396. [DOI: 10.3390/pharmaceutics14020396] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Díaz-perlas C, Oller-salvia B. Chemically Enhanced Peptide and Protein Therapeutics. Pharmaceutics 2023;15:827. [DOI: 10.3390/pharmaceutics15030827] [Reference Citation Analysis]
2 Yao P, Zhang Y, Zhang S, Wei X, Liu Y, Du C, Hu M, Feng C, Li J, Zhao F, Li C, Li Z, Du L. Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis. Front Oncol 2022;12:1039882. [PMID: 36686767 DOI: 10.3389/fonc.2022.1039882] [Reference Citation Analysis]
3 Yamazaki S, Matsuda Y. Tag‐Free Enzymatic Modification for Antibody−Drug Conjugate Production. ChemistrySelect 2022;7. [DOI: 10.1002/slct.202203753] [Reference Citation Analysis]
4 Wei D, Mao Y, Wang H, Qu S, Chen J, Li J, Jiang B, Chen H. A mild phenoxysilyl linker for self-immolative release of antibody-drug conjugates. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.108091] [Reference Citation Analysis]
5 Agnihotri TG, Jadhav GS, Sahu B, Jain A. Recent trends of bioconjugated nanomedicines through nose-to-brain delivery for neurological disorders. Drug Deliv Transl Res 2022;12:3104-20. [PMID: 35570262 DOI: 10.1007/s13346-022-01173-y] [Reference Citation Analysis]
6 Wang SC, Yan XY, Yang C, Naranmandura H. The Landscape of Nucleic-Acid-Based Aptamers for Treatment of Hematologic Malignancies: Challenges and Future Directions. Bioengineering 2022;9:635. [DOI: 10.3390/bioengineering9110635] [Reference Citation Analysis]
7 Pander G, Uhl P, Kühl N, Haberkorn U, Anderl J, Mier W. Antibody-drug conjugates: What drives their progress? Drug Discov Today 2022;27:103311. [PMID: 35787480 DOI: 10.1016/j.drudis.2022.06.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Dy G. Novel Biomarkers and Drug Targets in Non-Small Cell Lung Cancer. EMJ 2022. [DOI: 10.33590/emj/10113934] [Reference Citation Analysis]
9 Mishra AK, Ali A, Dutta S, Banday S, Malonia SK. Emerging Trends in Immunotherapy for Cancer. Diseases 2022;10:60. [DOI: 10.3390/diseases10030060] [Reference Citation Analysis]
10 Desantis J, Mammoli A, Eleuteri M, Coletti A, Croci F, Macchiarulo A, Goracci L. PROTACs bearing piperazine-containing linkers: what effect on their protonation state? RSC Adv 2022;12:21968-77. [PMID: 36043064 DOI: 10.1039/d2ra03761k] [Reference Citation Analysis]
11 Matikonda SS, McLaughlin R, Shrestha P, Lipshultz C, Schnermann MJ. Structure-Activity Relationships of Antibody-Drug Conjugates: A Systematic Review of Chemistry on the Trastuzumab Scaffold. Bioconjug Chem 2022. [PMID: 35801843 DOI: 10.1021/acs.bioconjchem.2c00177] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Wang X, Zhou Q, Li X, Gan X, Liu P, Feng X, Fang G, Liu Y. Insights into Aptamer-Drug Delivery Systems against Prostate Cancer. Molecules 2022;27:3446. [PMID: 35684384 DOI: 10.3390/molecules27113446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]